The National Drug and Health Products Authority Act, 2026

A New Era for Health Product Regulation in Uganda

On April 29, 2026, President Yoweri Museveni assented to the National Drug and Health Products Authority Act, 2026, marking a major shift in how health products are regulated in Uganda.

This new law repeals the National Drug Policy and Authority Act (1993) and introduces a broader, more modern regulatory system designed to reflect today’s complex healthcare environment.

Why This Reform Matters

For over three decades, Uganda’s regulatory framework focused primarily on medicines. While effective for its time, it did not fully address the rapid evolution of healthcare products such as biologics, diagnostics, and medical technologies.

According to the Parliament of Uganda briefing on the National Drug and Health Products Authority Bill the previous law had notable gaps, particularly in regulating emerging product categories and strengthening enforcement mechanisms.

The 2026 Act responds to these changes by introducing a comprehensive, lifecycle-based approach to regulation, ensuring oversight from product development through to post-market use.

The changes are also intended to propel Uganda’s regulatory authority to a much needed and desired WHO maturity ML3 status. This desired level of regulation will transform Uganda’s healthcare landscape by ensuring international safety standards, boosting local pharmaceutical manufacturing, and enabling global export opportunities through increased regulatory trust.

From NDA to NDHPA: What Has Changed

One of the most significant reforms is the transformation of the regulatory authority.

As highlighted when Parliament passed sweeping reforms on medicines, the former National Drug Authority has now evolved into the National Drug and Health Products Authority (NDHPA), with an expanded mandate covering the full spectrum of health products. 

The Authority now oversees:

  • Manufacturing
  • Import and export
  • Distribution and supply
  • Storage and dispensing
  • Post-market surveillance

This shift introduces greater consistency, accountability, and control across the healthcare system.

A Much Broader Scope of Regulation

The new Act significantly expands what falls under regulatory control.

As outlined in the same parliamentary reforms summary, the Act now covers a wide range of products beyond traditional medicines, including;

  • Vaccines and biological products
  • Medical devices and diagnostics
  • Cosmetics (containing parabens, phthalates, hydroquinone, retinoids or sunscreen)
  • Nutritional and dietary supplements
  • Public health products

This aligns Uganda with global regulatory approaches that apply risk-based oversight across multiple product categories.

How the Regulatory System Now Works

Product Evaluation and Registration: All products must be evaluated for safety, quality, and efficacy before they can enter the market.

Licensing Requirements: Entities involved in manufacturing, importation, and distribution must obtain appropriate licenses from the Authority.

Post-Market Surveillance: Once products are on the market, they remain subject to ongoing monitoring, including adverse event reporting and risk management.

This lifecycle approach strengthens oversight and reduces the risk of substandard or falsified products reaching patients.

Stronger Compliance and Enforcement

A defining feature of the 2026 Act is its emphasis on enforcement.

Advertising and Promotion Controls: All health product advertisements must be approved, and misleading claims are strictly prohibited.

Clinical Trial Oversight: Clinical trials are subject to stricter authorization, ethical review, and monitoring requirements.

Penalties and Legal Consequences: Non-compliance may result in:

  • Significant financial penalties
  • Suspension or revocation of licenses
  • Criminal liability, including imprisonment

This represents a shift toward a deterrence-based regulatory environment.

Special Provisions for Emergencies

The Act introduces flexibility in situations where immediate access to treatment is critical.

It allows for controlled use of unapproved products in:

  • Public health emergencies
  • Life-threatening conditions
  • Compassionate use scenarios

This ensures timely access to essential interventions while maintaining regulatory oversight.

It also supports flexibility as the
‘nitty-gritties’ of the act can be ironed out through guidelines which are much
easier to correct than the actual act.

What This Means for Industry and Stakeholders

The Act raises the bar for compliance while creating clearer regulatory pathways.

Pharmaceutical and Biotech Companies: Will face stricter regulatory requirements but benefit from improved clarity and credibility in the market.

Medical Device and Diagnostic Sector: Now operates under a formal regulatory framework, introducing classification, registration, and vigilance requirements.

Nutraceuticals and Cosmetics Industries: Will experience increased scrutiny, particularly regarding safety and product claims.

Healthcare Professionals: Must align with approved uses and comply with reporting obligations.

Patients and the Public: Stand to benefit from improved product safety, quality assurance, and protection from substandard products.

Industry concerns have already been raised, as reported by the Monitor (Scientists petition Museveni over the drugs authority bill), highlighting debates around implementation and sector impact.

Ongoing Discussions and Industry Perspectives

While the Act is widely viewed as progressive, it has generated discussion among stakeholders.

Key considerations include:

  • The potential impact on local manufacturing capacity
  • Role definitions across different professional groups
  • Practical implementation challenges

These discussions highlight the importance of clear implementation of regulations and stakeholder engagement.

What Happens Next?

The success of the Act will depend on effective implementation.

Key next steps include:

  • Development of detailed regulations and guidelines
  • Institutional capacity building within the Authority
  • Digital transformation of regulatory processes
  • Industry readiness and compliance alignment

Final Thoughts

The National Drug and Health Products Authority Act, 2026 is more than a legislative update, it represents a fundamental transformation of Uganda’s healthcare regulatory ecosystem.

For organizations operating in Uganda and across Africa, it signals a clear shift toward higher regulatory expectations, stronger enforcement, and structured market oversight.